Literature DB >> 25384535

Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris.

S Y Naseer1, K Seiffert-Sinha, A A Sinha.   

Abstract

With their near-universal presence in patients and ease of clinical measurement, anti-desmoglein (Dsg) antibodies serve as primary candidates for creating prognostic tools in Pemphigus vulgaris (PV). Although the desmoglein compensation hypothesis postulates a clear relationship between anti-Dsg autoantibodies and clinical phenotype in PV, recent studies have questioned the fidelity of this hypothesis as a predictor of lesion morphology. Moreover, few studies address the association of anti-Dsg antibodies to other clinical parameters such as disease phase and age at onset. Using the largest patient repository to date in PV, we present a detailed analysis of anti-desmoglein antibody profiles across a comprehensive range of dynamic (disease phase, therapy, lesion morphology) and temporal (disease duration, age at sampling, age at onset) clinical parameters. Our data highlight the non-traditional but key role of anti-Dsg1 levels in tracking disease activity. We show that declining anti-Dsg1 levels may predict progression from active phase to early remission and long-term maintenance of remission, regardless of lesion morphology. In contrast, many remittent patients have elevated levels of anti-Dsg3 without lesional activity. Furthermore, we describe a unique subset of remittent patients that develop chronic transient lesions (lasting <1 week) in the setting of elevated anti-Dsg3 levels but do not meet the consensus criteria for active phase. Re-classification of patients with transient lesions as "active" may shed new light on pathophysiological processes underlying cycles of blister formation and rapid spontaneous healing in PV. Additionally, we provide evidence for the potential attenuation of the immune response with prolonged disease duration. Our data fit into the broader effort of immunoprofiling to promote data-informed decision-making regarding diagnosis, prognosis and treatment of complex diseases.

Entities:  

Keywords:  Age at onset; Immunoprofiling; disease duration; disease phase; lesion morphology

Mesh:

Substances:

Year:  2014        PMID: 25384535     DOI: 10.3109/08916934.2014.976629

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

Review 1.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

Review 2.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis.

Authors:  Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

3.  Anti-Thyroid Peroxidase Reactivity Is Heightened in Pemphigus Vulgaris and Is Driven by Human Leukocyte Antigen Status and the Absence of Desmoglein Reactivity.

Authors:  Kristina Seiffert-Sinha; Shahzaib Khan; Kristopher Attwood; John A Gerlach; Animesh A Sinha
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

4.  Mechanisms of Trx2/ASK1-Mediated Mitochondrial Injury in Pemphigus Vulgaris.

Authors:  Bin Wei; Fenghe Li
Journal:  Biomed Res Int       Date:  2021-02-23       Impact factor: 3.411

5.  Autoantibodies against Desmoglein 1 and 3 in South Tunisian pemphigus.

Authors:  Ameni Jerbi; Hend Hachicha; Sawsan Feki; Olfa Abida; Emna Bahloul; Khadija Sellami; Amina Bouzid; Hamida Turki; Abderrahmen Masmoudi; Hatem Masmoudi
Journal:  Tunis Med       Date:  2021 Octobre

6.  Case report: Documentation of cutaneous only pemphigus vulgaris without history of mucosal lesions in North America.

Authors:  John Baker; Kristina Seiffert-Sinha; Animesh A Sinha
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

7.  Desmoglein compensation hypothesis fidelity assessment in Pemphigus.

Authors:  Lauren Sielski; John Baker; Michael C DePasquale; Kristopher Attwood; Kristina Seiffert-Sinha; Animesh A Sinha
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

8.  Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.

Authors:  Hoorieh Alaeen; Roja Toosi; Hamidreza Mahmoudi; Kamran Balighi; Soheil Tavakolpour; Amir Teimoupour; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2019-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.